Insider Buying: XOMA Co. (NASDAQ:XOMA) Director Acquires 17,935 Shares of Stock

XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber bought 17,935 shares of the business’s stock in a transaction dated Thursday, April 3rd. The stock was purchased at an average price of $25.24 per share, for a total transaction of $452,679.40. Following the acquisition, the director now directly owns 16,524 shares of the company’s stock, valued at approximately $417,065.76. The trade was a -1,271.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

XOMA Price Performance

Shares of XOMA stock opened at $19.23 on Tuesday. The company has a market cap of $230.36 million, a PE ratio of -5.53 and a beta of 1.00. The business has a 50 day moving average of $22.92 and a 200 day moving average of $26.51. XOMA Co. has a 52 week low of $18.35 and a 52 week high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA (NASDAQ:XOMA) last posted its earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $8.70 million during the quarter, compared to analysts’ expectations of $8.75 million. As a group, equities research analysts forecast that XOMA Co. will post -1.41 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $104.00 price target on shares of XOMA in a research report on Friday, March 28th. StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a report on Thursday, April 3rd.

Institutional Trading of XOMA

Several large investors have recently bought and sold shares of XOMA. Woodline Partners LP raised its position in shares of XOMA by 63.9% in the 4th quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after acquiring an additional 60,927 shares in the last quarter. JPMorgan Chase & Co. grew its stake in XOMA by 238.9% in the fourth quarter. JPMorgan Chase & Co. now owns 12,089 shares of the biotechnology company’s stock worth $318,000 after purchasing an additional 8,522 shares during the period. Barclays PLC raised its holdings in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in XOMA during the fourth quarter valued at $206,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of XOMA by 89.8% during the 4th quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company’s stock valued at $423,000 after buying an additional 7,619 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.